Why this vertical sits at Meta's highest enforcement tier
Weight-loss and GLP-1 telehealth advertising lives under Meta's most-restrictive policy category: Drugs and Pharmaceuticals (Meta's canonical restricted industry #11). Enforcement is categorical, which means Meta's AI risk model treats GLP-1-adjacent content with elevated scrutiny regardless of how compliant the specific ad appears.
The operational implications:
- Some false-positive rejections are structurally baked in. Even fully compliant ads get rejected; the appeal pipeline exists because Meta itself acknowledges the over-rejection rate in this category.
- Account-level disablement triggers fast. Repeat policy rejections on a single ad account drive disablement within 30 to 60 days.
- Business-identity reputation is the real currency. Meta correlates campaign profile, landing page, and payment behavior across all accounts under one business identity. One identity with multiple disablements gets the entire Business Manager's account-creation cap dropped.
- Compounded GLP-1 is enforced separately from FDA-approved GLP-1. Meta treats these as different products. Compounded semaglutide and tirzepatide require explicit "not FDA-approved" disclaimers and licensed-prescriber documentation.
Across our coverage in this vertical, GLP-1 telehealth accounts experience suspension cascades at materially higher rates than supplements or non-restricted verticals, and the cascade timing is faster (ComplyAi Intelligence Graph, Q2 2026). The Enforcement Behavior signature is category-level, not creative-level, which is why compliance work here has to address the vertical-level risk model, not just the individual ad.
The authorization gate that stops most GLP-1 ads before category-level enforcement even fires
The most common GLP-1 telehealth enforcement pattern in our corpus is not creative-level rejection or restriction. It is the account-never-authorized failure mode: advertisers who launch GLP-1 campaigns without the prerequisite third-party certification, whose ads then get rejected across the board regardless of creative compliance.
Meta's Prescription Drugs policy (Business Help Center: "About Meta's Prescription Drugs advertising policy") documents the gate. Prescription-drug advertising requires prior Meta authorization, and authorization is only available to three entity classes: pharmaceutical manufacturers, online pharmacies, and telehealth providers.
For GLP-1 telehealth specifically, the authorization path is:
- Certify the business with LegitScript. LegitScript is the independent third-party verifier Meta relies on for prescription-drug advertiser eligibility. Certification is per country. Without an active LegitScript certification, Meta will not accept the application in the next step.
- Submit for Meta authorization. Once LegitScript-certified, apply through the Authorizations and verifications tab in Meta Business Suite. The application requires the LegitScript-certified URL, business name, and the specific ad accounts to authorize.
- Maintain LegitScript. Meta revokes authorization if the LegitScript certification lapses.
Pharmaceutical manufacturers have an alternative path (Meta's internal review, requiring FDA registration or equivalent) that does not depend on LegitScript. Telehealth providers do not have this option; LegitScript is the mandatory route for that entity class.
Country scope is narrow. Meta permits prescription-drug advertising in three countries only: United States, Canada, and New Zealand. Advertisers must be certified in the specific country they target, and audiences must be 18 or older.
What the authorization allows. Meta's policy explicitly permits authorized telehealth advertisers to run ads with efficacy comparisons, sales-language CTAs, delivery details, price disclosures, and telehealth-consultation language. The full functional range of prescription-drug promotion sits behind the gate. The categorical-enforcement mechanics in the next section operate downstream, filtering compliant vs non-compliant creative from within the authorized advertiser pool.
On compounded semaglutide and the pharmaceutical-manufacturer definition. Meta's public entity-type language includes "compounding" as one of the qualifying activities under Pharmaceutical Manufacturers. A compounding pharmacy that produces semaglutide can therefore route through the manufacturer authorization path (Meta's internal review or LegitScript). Whether Meta's enforcement system treats a specific compounded product with the same signal weight as an FDA-approved brand is a separate operational question, and one that varies by product and marketing surface. Section 02 covers what we observe about that variance.
